#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Richter's syndrome Precursor T-lymphoblastic lymphoma/leukaemia recurrent Narcolepsy Marginal zone lymphoma refractory Synovial sarcoma recurrent Paroxysmal nocturnal haemoglobinuria Anal fistula Hereditary optic atrophy Wiskott-Aldrich syndrome Cutaneous calcification Pleomorphic liposarcoma Pulmonary tuberculosis Renal cancer metastatic Urethral valves Gastrooesophageal cancer More trials…

    Learn about Rare Diseases

    Adrenocortical carcinoma – Diagnostics CADASIL – Treatment Mucopolysaccharidosis III – Treatment Hereditary motor and sensory neuropathy – Trials in Disease Hereditary ataxia – Diagnostics Erdheim-Chester disease – Life with Disease Rhabdomyosarcoma recurrent – Treatment Systemic mastocytosis – Treatment Advanced systemic mastocytosis – Treatment Prolymphocytic leukaemia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cariprazine Emapalumab Clofutriben Aminohippuric Acid Tozinameran Ruxotemitide Pseudoephedrine Hydrochloride GSKVX000000030810 Daunorubicin Hydrochloride ASP2957 Ketamine Hydrochloride Aztreonam Adapalene [14C] DC-806 Tenofovir Disoproxil Nesolicaftor Altizide Rocatinlimab Levomepromazine Hydrochloride Milademetan More therapies…

    Learn about Your Condition

    Neurofibrosarcoma Carotid artery occlusion Colon cancer metastatic Aplasia pure red cell Stress Spondylolisthesis Juvenile psoriatic arthritis Ovarian epithelial cancer Death neonatal Hypertrophic scar Haemoglobinuria Pemphigus Micrographic skin surgery Vitamin D deficiency Hypersensitivity More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Twoja Przychodnia Poznańskie Centrum Medyczne Sp. z…

Twoja Przychodnia Poznańskie Centrum Medyczne Sp. z o.o.

ul. Marcelińska 92, Poznan, 60-324, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

    Recruiting

    1 1 1
    Investigated Drugs:
    • MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN
    • IM-101
    • HAEMOPHILUS TYPE B POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID ADSORBED ON ALUMINIUM PHOSPHATE
    Bulgaria Italy Poland Spain

  • A study to evaluate the safety of dazodalibep in patients with Sjögren’s Syndrome over a long period of time

    Recruiting

    3 1 1
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • Evaluation of CIT-013 at two dose levels compared to placebo for treating moderate to severe Hidradenitis Suppurativa

    Recruiting

    2 1
    Investigated Diseases:
    • Hidradenitis
    Germany The Netherlands Poland Spain

  • Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

    Recruiting

    2 1
    Investigated Drugs:
    • RO7837195
    Czechia France Germany Italy Poland

  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15

  • Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines

    Recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Zasocitinib
    • Apremilast
    Belgium Bulgaria Croatia Czechia Estonia Germany +6

  • Study on the Long-Term Safety of Dazukibart in Patients with Idiopathic Inflammatory Myopathies, Including Dermatomyositis and Polymyositis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatomyositis
    • Idiopathic inflammatory myopathy
    • Polymyositis
    Investigated Drugs:
    • Betamethasone
    • CHLOROQUINE PHOSPHATE
    • Dazukibart
    Bulgaria Hungary Italy Poland Spain Sweden

  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Obefazimod
    Belgium Czechia France Germany Hungary Italy +5

  • Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

    Recruiting

    3 1 1
    Investigated Drugs:
    • Cenerimod
    Bulgaria Czechia France Germany Greece Poland +3

  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    2 1
    Investigated Drugs:
    • Morf-057
    Austria Bulgaria Croatia Czechia Estonia France +8
Previous Page
1 2 3 4 … 7
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!